沙利度胺治疗皮肤结节病
Treatment of cutaneous sarcoidosis with thalidomide.
作者信息
Nguyen Yên Thi, Dupuy Alain, Cordoliani Florence, Vignon-Pennamen Marie Dominique, Lebbé Céleste, Morel Patrice, Rybojad Michel
机构信息
Dermatology Department, Hôspital Saint-Louis, Paris, France.
出版信息
J Am Acad Dermatol. 2004 Feb;50(2):235-41. doi: 10.1016/j.jaad.2003.07.006.
BACKGROUND
Although systemic corticosteroids are effective against cutaneous sarcoidosis, alternative therapies are needed.
OBJECTIVE
We sought to assess the efficacy and tolerance of thalidomide for cutaneous sarcoidosis.
METHODS
We performed a retrospective evaluation of thalidomide (100-200 mg/d) in 12 consecutive patients with cutaneous sarcoidosis treated in a university hospital between 2000 and 2002.
RESULTS
Cutaneous lesions regressed within 1 to 5 months, with an average time of 2 to 3 months for 10 patients. In all, 4 patients achieved complete responses, 6 had partial responses, and 2 had no regression. Nasopharyngeal, pulmonary neurologic, and hepatic symptoms were also attenuated. Thalidomide was well tolerated. The main adverse effect was deep vein thrombosis in 1 patient.
CONCLUSION
Thalidomide efficacy and tolerance in patients with cutaneous sarcoidosis merits further evaluation in a controlled trial.
背景
尽管全身用皮质类固醇对皮肤结节病有效，但仍需要其他替代疗法。
目的
我们试图评估沙利度胺对皮肤结节病的疗效和耐受性。
方法
我们对2000年至2002年间在一家大学医院接受治疗的12例连续性皮肤结节病患者使用沙利度胺（100 - 200mg/天）进行了回顾性评估。
结果
皮肤损害在1至5个月内消退，10例患者的平均消退时间为2至3个月。总共有4例患者获得完全缓解，6例部分缓解，2例无消退。鼻咽、肺部、神经和肝脏症状也有所减轻。沙利度胺耐受性良好。主要不良反应是1例患者发生深静脉血栓形成。
结论
沙利度胺对皮肤结节病患者的疗效和耐受性值得在对照试验中进一步评估。
Zotero 插件